Business context and reporting period
Embecta’s Form 10-Q covers the three and six months ended March 31, 2022. The results are for BD’s Diabetes Care Business, which sells insulin pen needles, syringes and related products. Embecta’s spin-off from BD was completed April 1, 2022; accordingly, these are historical combined statements, not results of a full quarter operating as an independent company. Management cautions that allocated costs and historical results may not reflect standalone costs or future performance.
Financial performance
All amounts are in millions of dollars except per-share amounts and percentages.
| Metric | Three months ended March 31, 2022 | Year-over-year | Six months ended March 31, 2022 | Year-over-year |
|---|---|---|---|---|
| Revenue | $274.5 | Down 3.4% | $563.8 | Down 1.0% |
| Gross profit / margin | $191.2 / 69.7% | $196.3 / 69.1% | $395.1 / 70.1% | $387.6 / 68.1% |
| Operating income | $98.9 | Down 21.8% | $215.5 | Down 14.0% |
| Net income | $79.6 | Down 26.2% | $178.4 | Down 16.3% |
| Diluted EPS | $1.38 | Versus $1.87 | $3.09 | Versus $3.69 |
| Adjusted EBITDA (non-GAAP) | $116.8 | Down $24.8 | $254.8 | Down $35.0 |
For the quarter, reported revenue fell $9.7, including $6.0 of unfavorable foreign-exchange effects and approximately $3.7 of lower volume, mainly in the U.S. and Europe. Constant-currency revenue declined 1.3%. For the six-month period, constant-currency revenue increased 0.2%; unfavorable currency and price/volume in the U.S. were partly offset by emerging-market volume growth.
Cash flow, liquidity and debt
Six-month operating cash flow was $321.4, versus $241.1 a year earlier; investing cash outflow was $10.1, versus $18.2; and financing cash outflow was $44.2, versus $222.9. Operating cash flow included a $133.3 decrease in trade receivables, primarily associated with factoring receivables to BD, and inventory rose $10.0 as Embecta built stock ahead of separation. Capital expenditures were $9.7.
At March 31, 2022, cash was $264.3 and current assets were $426.5 against current liabilities of $168.9. Debt included $950.0 of term loans and $500.0 of 5.00% senior secured notes, plus $200.0 principal amount of 6.75% notes issued to BD (reported at $197.0 on the balance sheet). The revolving facility provides up to $500.0 and had no borrowings outstanding. The term loan bears interest at SOFR plus 3.00%, subject to a 0.50% floor; the initial rate was 3.65%. Debt agreements contain leverage and other restrictive covenants; Embecta reported compliance at quarter-end. Moody’s and S&P assigned Ba3 and B+ ratings, respectively.
Material changes versus prior comparable periods
- Quarterly revenue and profit declined, while gross margin improved by 0.6 percentage points. Six-month gross margin improved by 2.0 percentage points, partly because the prior-year period included a $10.0 impairment charge.
- Selling and administrative expense rose 19.9% for the quarter and 18.4% for six months, reflecting higher marketing and advertising spending and increased staffing in preparation for standalone operations.
- Research and development expense rose 27.7% for the quarter and 23.5% for six months, primarily reflecting investment in new products, including an insulin patch pump.
- Embecta incurred $7.4 of separation and stand-up costs in the quarter and $15.8 year to date; no such costs were reported in the prior-year periods. Interest expense was $4.9 following debt issuance.
- Balance-sheet changes reflect the separation, debt financing and asset transfers to BD. Property, plant and equipment declined $95.3 from September 30, 2021, largely due to transferred assets.
Outlook, commentary and risks
The filing provides no quantified revenue or earnings guidance. Management said it expects higher costs under the transition services arrangement and ongoing standalone-company expenses, along with one-time separation costs; some separation costs are expected to decline after the spin-off. It also expected inventory-building to continue through the remainder of fiscal 2022 and said it believed available cash, operating cash flows and financing arrangements would meet short-term liquidity needs.
Key uncertainties include the costs and execution of separation, reliance on BD under transition, supply, manufacturing and distribution agreements, competition and pricing, raw-material availability and costs, foreign exchange, interest rates and leverage, COVID-19-related disruption, and the Russia-Ukraine conflict’s potential effects on markets, supply chains, inflation, currencies and cybersecurity. Russia and Ukraine sales were not material in the reported periods. No material legal proceedings or probable, estimable material legal loss were reported; management cautioned that contingencies remain subject to uncertainty.
Important facts for investors to verify
- Track post-spin operating results and standalone costs against the BD-allocated historical expense base.
- Monitor debt service, variable-rate term-loan exposure, leverage-covenant headroom and use of the revolving facility.
- Assess whether inventory growth and receivables factoring support recurring cash generation; six-month cash flow benefited substantially from lower receivables.
- Follow revenue volume, pricing and currency trends by geography, as well as customer concentration: three customers represented approximately 43.6% of quarterly revenue.
- Review execution and cost implications of BD transition, supply, manufacturing, logistics and other separation agreements.